➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Dow
Johnson and Johnson
Boehringer Ingelheim

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

ADMELOG SOLOSTAR Drug Profile


Email this page to a colleague

« Back to Dashboard

Recent Litigation for ADMELOG SOLOSTAR

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc.2016-11-30
Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc.2016-11-29

See all ADMELOG SOLOSTAR litigation

PTAB Litigation
PetitionerDate
Pfizer Inc.2019-05-02
Mylan Pharmaceuticals Inc.2018-10-29
Mylan Pharmaceuticals Inc2018-09-10

See all ADMELOG SOLOSTAR litigation

Patent Text Search: US Patents for ADMELOG SOLOSTAR

These patents were identified by searching patent claims

International Patents for ADMELOG SOLOSTAR

Country Patent Number Estimated Expiration
Canada 2750115   Get Started Free
South Africa 201200224   Get Started Free
Portugal 2476430   Get Started Free
Russian Federation 2004118503   Get Started Free
Israel 211053   Get Started Free
World Intellectual Property Organization (WIPO) 2010122385   Get Started Free
Spain 2570937   Get Started Free
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for ADMELOG SOLOSTAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
300753 Netherlands   Get Started Free PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
132016000070123 Italy   Get Started Free PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
122016000049 Germany   Get Started Free PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
132016000025345 Italy   Get Started Free PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828
CA 2015 00043 Denmark   Get Started Free PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
300822 Netherlands   Get Started Free PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
CR 2016 00031 Denmark   Get Started Free PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
Medtronic
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.